Forbion Secures Record €2.3 Billion Across Two Funds, Offering Critical Boost to European Biotech Sector
admin The Netherlands-based venture capital firm Forbion has successfully closed two new funds, Forbion Growth Opportunities...
biotech
Advancing the Frontier of Pediatric Oncology: How Tailored Immunotherapies Are Revolutionizing Childhood Cancer Treatment
Over the past several decades, the landscape of childhood cancer treatment has undergone a dramatic...
Sanofi and Regeneron Fortify Immunology Alliance with Focus on Next-Generation IL-4/IL-13 Inhibitors, Bolstering Pipeline Against Patent Expiry
Paris, France, and Tarrytown, New York – In a strategic move designed to extend their...
The Rudensky Symposium Celebrates a Legacy of Immunological Discovery and Mentorship, Charting New Frontiers in Cancer Research
The Rudensky Symposium on Immunity, Inflammation and Tolerance, held on August 27–28, 2026, transcended the...
The European Association for the Study of Diabetes Annual Meeting Illuminates Next-Generation Obesity Treatments and Intensifying Pharmaceutical Race
Milan, Italy – The annual meeting of the European Association for the Study of Diabetes...
Pharmaceutical Industry Reshapes Leadership and Bolsters Pipelines with Key Approvals and Strategic Acquisitions
The biopharmaceutical sector is experiencing a period of significant strategic realignment, marked by a high-profile...
Cancer Research Institute Commits Record $34.4 Million to Propel Cancer Immunotherapy Research Amidst Global Funding Uncertainty
In a landscape increasingly defined by fiscal prudence and scientific funding instability, the Cancer Research...
Victoria Ann Michelis Fund Fuels Pioneering Research in Ovarian Cancer and Supports Underdogs
The indelible spirit of Victoria “Vicky” Ann Michelis, a woman who championed the underdog and...
Roche’s Fenebrutinib Faces Regulatory Scrutiny Despite Landmark FDA Application Acceptance for Multiple Sclerosis.
The U.S. Food and Drug Administration (FDA) has accepted Roche’s application for fenebrutinib, a Bruton’s...
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
Bristol Myers Squibb (BMS) has confirmed that its investigational drug, admilparant, an LPA1 receptor inhibitor,...
